News
Clinical Trials Arena on MSN20h
Ionis doses first subject in Phase III trial of Angelman syndrome therapyIonis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582, aimed at treating individuals with Angelman syndrome (AS), a rare ...
The firm expects to complete enrolling the REVEAL trial, in which patients will receive the ASO, dubbed ION582, in 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback